FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?

The bicyclic nucleoside analogue (BCNA) Cf1743 and its orally bioavailable prodrug FV-100 have unique potential as varicella-zoster virus (VZV) inhibitors to treat herpes zoster (shingles) and the therewith associated pain, including post-herpetic neuralgia (PHN). The anti-VZV activity of Cf1743 dep...

Descripción completa

Detalles Bibliográficos
Autor principal: De Clercq, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028626/
https://www.ncbi.nlm.nih.gov/pubmed/35458500
http://dx.doi.org/10.3390/v14040770
_version_ 1784691667848134656
author De Clercq, Erik
author_facet De Clercq, Erik
author_sort De Clercq, Erik
collection PubMed
description The bicyclic nucleoside analogue (BCNA) Cf1743 and its orally bioavailable prodrug FV-100 have unique potential as varicella-zoster virus (VZV) inhibitors to treat herpes zoster (shingles) and the therewith associated pain, including post-herpetic neuralgia (PHN). The anti-VZV activity of Cf1743 depends on a specific phosphorylation by the VZV-encoded thymidine kinase (TK). The target of antiviral action is assumed to be the viral DNA polymerase (or DNA synthesis in the virus-infected cells).
format Online
Article
Text
id pubmed-9028626
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90286262022-04-23 FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis? De Clercq, Erik Viruses Review The bicyclic nucleoside analogue (BCNA) Cf1743 and its orally bioavailable prodrug FV-100 have unique potential as varicella-zoster virus (VZV) inhibitors to treat herpes zoster (shingles) and the therewith associated pain, including post-herpetic neuralgia (PHN). The anti-VZV activity of Cf1743 depends on a specific phosphorylation by the VZV-encoded thymidine kinase (TK). The target of antiviral action is assumed to be the viral DNA polymerase (or DNA synthesis in the virus-infected cells). MDPI 2022-04-07 /pmc/articles/PMC9028626/ /pubmed/35458500 http://dx.doi.org/10.3390/v14040770 Text en © 2022 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
De Clercq, Erik
FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?
title FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?
title_full FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?
title_fullStr FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?
title_full_unstemmed FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?
title_short FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?
title_sort fv-100 for the treatment of varicella-virus (vzv) infections: quo vadis?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028626/
https://www.ncbi.nlm.nih.gov/pubmed/35458500
http://dx.doi.org/10.3390/v14040770
work_keys_str_mv AT declercqerik fv100forthetreatmentofvaricellavirusvzvinfectionsquovadis

Ejemplares similares